# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
BTIG analyst Robert Hazlett maintains Rani Therapeutics Hldgs (NASDAQ:RANI) with a Buy and raises the price target from $7 t...
Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (NASDAQ:RANI), a clinical-stage biotherapeutic...
HC Wainwright & Co. analyst Mitchell Kapoor maintains Rani Therapeutics Hldgs (NASDAQ:RANI) with a Buy and raises the pr...
Rani Therapeutics Hldgs (NASDAQ:RANI) reported quarterly losses of $(0.29) per share which beat the analyst consensus estimate ...
U.S. stock futures were higher this morning, with the Dow futures gaining over 50 points on Thursday.
Shares of The Travelers Companies, Inc. (NYSE: TRV) fell sharply during Wednesday’s session following first-quarter earnings.